Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

4 weeks ago 5

TipRanks

Tue, February 24, 2026 astatine 7:53 AM CST 1 min read

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive plus acquisition statement to merchantability its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205M upon the closing of the transaction. In December 2023, Sentynl Therapeutics assumed afloat work for the improvement and commercialization of ZYCUBO from Cyprium. The PRV was issued upon support of ZYCUBO by the U.S. Food and Drug Administration connected January 12, 2026. Pursuant to the transaction with Sentynl, the PRV was instantly transferred to Cyprium. Cyprium remains eligible to person tiered royalties connected nett income of ZYCUBO and up to $129M successful aggregate improvement and income milestones from Sentynl. Cyprium is besides obligated to wage 20% of the proceeds from a PRV merchantability to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health. The transaction is taxable to customary closing conditions, including expiration of the applicable waiting play nether the Hart-Scott Rodino Antitrust Improvements Act.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected FBIO:

Disclaimer & DisclosureReport an Issue

Fortress Biotech Gains FDA Approval for Menkes Treatment
Fortress Biotech, Cyprium denote FDA support of ZYCUBO
Largest get complaint increases among liquid names

Read Entire Article